Pharmaceutical composition for treatment of neurodegenerative brain disease comprising triflupromazine or pharmacurically acceptable salt thereof as an active ingredient

• Main Authors: KIM SEONG MUK, JEON HANNA, LEE DONGHEE, KIM HYE JU, KIM YOUNGSOO, SHIN JISU
• Format: Patent
• Language: English; Korean
• Published: 02.12.2019
• Subjects: FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES

Provided are a novel pharmaceutical composition and a method for amyloid aggregation inhibition and/or degradation, tau degradation and/or tau phosphorylation inhibition, and/or prevention and/or treatment of degenerative brain diseases. More specifically, provided are a pharmaceutical composition and a method for amyloid-beta aggregation inhibition and/or degradation, tau degradation and/or tau phosphorylation inhibition, and/or prevention and/or treatment of degenerative brain diseases, which contain triflupromazine or a pharmaceutically acceptable salt thereof as an active component. 아밀로이드 응집 억제 및/또는 분해, 및/또는 타우 분해 및/또는 타우 인산화 억제, 및/또는 퇴행성 뇌질환의 예방 및/또는 치료를 위한 신규한 약학 조성물 및 방법이 제공된다. 보다 구체적으로, 트리플루프로마진 (Triflupromazine) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 아밀로이드-베타 응집 억제 및/또는 분해, 타우 분해 및/또는 타우 인산화 억제, 및/또는 퇴행성 뇌질환의 예방 및/또는 치료를 위한 약학 조성물 및 방법이 제공된다.